, Katherine Cheng 2, 3 , Zandra Walton 2, 3 , Yuchuan Wang 4, 5, 6 , Hiromichi Ebi 1, 7 , Takeshi Shimamura Targeted therapies have demonstrated efficacy against specific subsets of molecularly defined cancers [1] [2] [3] [4] . Although most patients with lung cancer are stratified according to a single oncogenic driver, cancers harbouring identical activating genetic mutations show large variations in their responses to the same targeted therapy 1, 3 . The biology underlying this heterogeneity is not well understood, and the impact of co-existing genetic mutations, especially the loss of tumour suppressors [5] [6] [7] [8] [9] , has not been fully explored. Here we use genetically engineered mouse models to conduct a 'co-clinical' trial that mirrors an ongoing human clinical trial in patients with KRAS-mutant lung cancers. This trial aims to determine if the MEK inhibitor selumetinib (AZD6244) 10 increases the efficacy of docetaxel, a standard of care chemotherapy. Our studies demonstrate that concomitant loss of either p53 (also known as Tp53) or Lkb1 (also known as Stk11), two clinically relevant tumour suppressors 6, 9, 11, 12 , markedly impaired the response of Kras-mutant cancers to docetaxel monotherapy. We observed that the addition of selumetinib provided substantial benefit for mice with lung cancer caused by Kras and Kras and p53 mutations, but mice with Kras and Lkb1 mutations had primary resistance to this combination therapy. Pharmacodynamic studies, including positron-emission tomography (PET) and computed tomography (CT), identified biological markers in mice and patients that provide a rationale for the differential efficacy of these therapies in the different genotypes. These co-clinical results identify predictive genetic biomarkers that should be validated by interrogating samples from patients enrolled on the concurrent clinical trial. These studies also highlight the rationale for synchronous co-clinical trials, not only to anticipate the results of ongoing human clinical trials, but also to generate clinically relevant hypotheses that can inform the analysis and design of human studies.
Activating KRAS mutations are found in 15-30% of all patients with non-small cell lung cancer (NSCLC), and predict poor outcome in response to conventional treatment regimens 13, 14 . Preclinical studies have suggested that inhibition of MAPK/ERK kinase (MEK) may be effective against KRAS-mutant NSCLC 15 , prompting an ongoing human clinical trial comparing docetaxel monotherapy (standard of care) to docetaxel combined with the MEK inhibitor selumetinib (AZD6244). Although the sole genetic entry criteria for patients on this trial is the presence of KRAS mutations, the complexity of NSCLC dictates that many tumours will harbour concomitant genetic alterations that may modulate response to therapy. To mirror this human clinical trial in a murine co-clinical trial, and to investigate the modulating effects of concomitant tumour suppressor loss, we generated cohorts of genetically engineered mice with either Kras, Kras and p53 (Kras/p53) or Kras/Lkb1 mutant lung cancers. Activation of Kras(G12D) and inactivation of p53 or Lkb1 in the lung epithelium was achieved using nasal instillation of adenovirus encoding the CRE recombinase 7 . Mice with established disease, defined by tachypnoea, hypoxaemia on pulse oximetry 16 , and bulk disease on magnetic resonance imaging (MRI) 17 , were randomized to receive either docetaxel 16 , or docetaxel in combination with selumetinib. Treatment response was determined by serial MRI. Tumour volumes were reconstructed from the MRI images ( Supplementary Fig. 1a ) with a high level of interoperator reliability (Supplementary Fig. 1b ; 95% confidence interval, 225.6% to 131.4%). On the basis of these performance metrics, and paralleling human response criteria, we used a threshold of 30% change in tumour volume to define progressive disease and partial response.
For tumours with only Kras mutation, treatment with docetaxel monotherapy resulted in a modest rate of response, with 30% of mice achieving a partial response (Fig. 1a, c) . Mice bearing Kras tumours with concurrent loss of p53 or Lkb1 had markedly lower response rates to docetaxel treatment (5% and 0%, respectively), and more of these animals demonstrated progressive disease on MRI or progression to moribundity ( Fig. 1a and Supplementary Table 2 ). The addition of selumetinib to docetaxel treatment provided substantial benefit (Fig. 1b, c) , with the overall response rate increased to 92% in Krasmutant cancers (P 5 2.8 3 10
Kras/Lkb1 mutant cancers the addition of selumetinib to docetaxel led to only a modest improvement in overall response, with 33% of the mice achieving a partial response (Fig. 1b, c) . Compared to the other genotypes, Kras/Lkb1 mice had a significantly lower rate of response to combined treatment with selumetinib and docetaxel (P 5 0.0009, 3 3 2 contingency Fisher exact test).
The magnitude of change in volume confirmed that tumours with Kras or Kras/p53 mutations were considerably more responsive to combination therapy compared to docetaxel alone. In contrast, the addition of selumetinib did not significantly reduce the volume of tumours with compound Kras/Lkb1 mutations ( Fig. 1d and Supplementary Fig. 1c, d) . Concordantly, histopathological assessments of tumours collected after two doses of treatment revealed that the combination treatment increased apoptosis ( Fig. 1e and Supplementary Fig. 2a ) and reduced proliferation ( Fig. 1f and Supplementary Fig. 2b ) in the Kras and Kras/p53 tumours compared to docetaxel alone, but this was not observed in Kras/Lkb1 tumours (Fig. 1e , f and Supplementary Fig. 2a, b ). These results demonstrate that combined treatment with selumetinib and docetaxel induces apoptosis and decreases proliferation in Kras and Kras/p53 tumours, leading to antitumour efficacy, but that concomitant mutation of Lkb1 confers primary resistance to the combination treatment.
Because repeated tumour biopsies are difficult in patients, we explored the use of 18 F-fluoro-2-deoxy-glucose PET (FDG-PET) as an early response indicator that could be used in the clinic. Comparison of FDG avidity, quantified by standardized uptake value (SUV) 20, 21 in lung cancers across the three different genotypes showed an overall higher FDG uptake in both Kras/p53 and Kras/Lkb1 tumours compared to Kras tumours ( Fig. 2a ; P 5 0.02, one-way ANOVA). Expression of the glucose transporter GLUT1 (also known as SLC2A1) was elevated in Kras/Lkb1 mutant tumours ( Supplementary Fig. 3a) , consistent with the increased baseline FDG-PET signal. To determine if this finding was applicable to human patients, we determined the pre-treatment FDG avidity in nine patients with KRAS-mutated lung cancer. Tumours from three patients positive for LKB1 immunostaining had a mean maximum SUV (SUV max ) of 2.33, whereas tumours from six patients negative for LKB1 immunostaining had a mean SUV max of 8.75 ( Fig. 2b ; P 5 0.048, two-sided Wilcoxon).
We next used FDG-PET to assess early tumour metabolic changes after initiation of therapy. Treatment with docetaxel alone did not result in significant changes in tumour hypermetabolism in Kras-, Kras/p53-or Kras/Lkb1-tumour-bearing mice (Fig. 2c, d ). Of note, some of the murine Kras lung cancer nodules were not FDG avid ( Fig. 2a ) and these were the most sensitive to single-agent docetaxel (data not shown). In contrast, within 24 h of the first dose of treatment with docetaxel and selumetinib, tumour hypermetabolism was markedly suppressed in both Kras and Kras/p53 mice (Fig. 2c, d ). However, Kras/Lkb1-mutant tumours had no appreciable decrease in FDG avidity when treated with the combination (Fig. 2c, d ). Together, these results demonstrate that early changes in tumour metabolism measured by FDG-PET (Fig. 2c,  d ) are concordant with histopathological analysis of apoptosis and proliferation (Fig. 1e , f) and predict antitumour efficacy (Fig. 1a-c ) of docetaxel and selumetinib in treating Kras-mutant lung cancers.
To assess the pharmacodynamic effects of treatment on the MEK-ERK signalling axis, we assayed pathway activation using phospho-ERK immunostaining of lung cancer nodules. At baseline, the ERK pathway was most activated in Kras/p53-mutant tumours (Fig. 3a, b) . We observed substantially less phospho-ERK staining in Kras/Lkb1 tumours, suggesting that the MEK-ERK pathway is not highly activated in these cancers. Treatment with docetaxel did not alter phospho-ERK staining, but, as expected, the addition of selumetinib decreased MEK-ERK signalling in the Kras and Kras/p53 tumours (Fig. 3a, b) .
We further evaluated cellular signalling from short-term-treated lung cancer nodules by immunoblotting tumour lysates. Concordant with immunostaining (Fig. 3a) , elevated phospho-ERK and phospho-90RSK were observed in Kras/p53 tumours relative to the other genotypes Table 6 for detailed information).
RESEARCH LETTER (Fig. 3c and Supplementary Fig. 4a ). Kras/Lkb1 tumours displayed low basal activation of the MEK-ERK pathway ( Fig. 3c and Supplementary  Fig. 4a ), consistent with immunostaining (Fig. 3a) . Treatment with docetaxel had no discernable impact on the MEK-ERK pathway in any genotype (Fig. 3a-c and Supplementary Fig. 4b ). Although selumetinib alone resulted in decreased phospho-ERK, residual activity was still present (Fig. 3c and Supplementary Fig. 4b ). Treatment with both docetaxel and selumetinib more effectively eradicated phospho-ERK activity (Fig. 3c and Supplementary Fig. 4b ). Pharmacokinetic studies suggested that selumetinib levels were elevated in the serum and tumours of mice treated with selumetinib combined with docetaxel compared to selumetinib alone (Supplementary Table 3 ), perhaps providing a mechanism for the more potent suppression of MEK-ERK signalling by the combination (Fig. 3c) . The potential relevance of these findings to human disease was investigated by assessing phospho-ERK staining in a set of 57 human NSCLC tumour samples with known KRAS, p53 and LKB1 mutation status. Consistent with our findings in murine tumours, of seven patients harbouring the KRAS activating mutation, the three patients with concurrent p53 loss showed higher phospho-ERK activity (Fig. 3d) . 
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The decreased activation of ERK phosphorylation in Kras/Lkb1 tumours suggests that the proliferation of these tumours may be driven through other signalling pathways. On the basis of our prior studies 19, 22 , we investigated the activity of AKT and SRC in Kras/Lkb1 mutant tumours. Immunoblotting with activation-state-specific antibodies revealed that Kras/Lkb1-mutant tumours have heightened activation of both AKT and SRC ( Supplementary Fig. 3a, b) , consistent with the finding of increased FDG avidity in Kras/Lkb1 tumours (Fig. 2a, b) , because PI3K regulates expression of GLUT1 (Supplementary Fig. 3a) . These results suggest that concomitant mutation of Kras and Lkb1 may alter the signalling circuitry in tumour cells from one dependent on MEK-ERK (in Kras and Kras/p53 tumours) to one that has more active AKT and SRC pathways, resulting in primary resistance to docetaxel and selumetinib.
The concurrent human clinical trial does not include a treatment arm in which patients are treated with selumetinib alone, based on lack of efficacy in a phase II clinical trial in patients with NSCLC 23 , and on our preclinical data in Kras genetically engineered mice 19 . In mice with Kras, Kras/p53 and Kras/Lbk1 tumours, treatment with selumetinib alone resulted in a heterogeneous reduction in FDG-PET uptake ( Supplementary Fig. 5a ), consistent with pharmacodynamic evidence that selumetinib alone partially attenuates MEK-ERK signalling within tumours ( Fig. 3c and Supplementary Fig. 7c ). However, no partial responses were achieved in any genotype with selumetinib monotherapy, although there was attenuation of tumour growth compared to untreated controls ( Supplementary Fig. 5b ). Together, these data suggest that selumitinib as monotherapy modulates MEK-ERK signalling in Kras-driven tumours, but is insufficient for clinical benefit in mice and humans.
We determined the long-term benefit of combined treatment with docetaxel and selumetinib in the Kras-and Kras/p53-mutant mice compared to chronic treatment with docetaxel monotherapy. We did not assess long-term treatment outcome in Kras/Lkb1 animals given the primary resistance to both treatments in these animals (Figs 1-3 ). In mice with Kras tumours, treatment with docetaxel alone stabilized disease for several weeks, whereas the addition of selumetinib caused frank tumour regression and slower tumour re-growth ( Fig. 4a and Supplementary Fig. 6a, b) . Accordingly, the addition of selumetinib to docetaxel significantly prolonged progression-free survival (Fig. 4b) . In mice with Kras/p53 tumours, treatment with docetaxel alone largely resulted in progressive disease, whereas animals treated with a combination of docetaxel and selumetinib had initial disease regression before progression ( Fig. 4a and Supplementary Fig. 6c ), resulting in prolonged progression-free survival (Fig. 4c ). These results demonstrate that the enhanced response to treatment with combined therapy translates to improved progression-free survival, albeit not outright cure, in mice bearing Kras-and Kras/p53-mutant tumours.
To investigate mechanisms of resistance upon disease progression, tumour nodules were isolated from moribund animals after long-term treatment with docetaxel and selumetinib. In all animals examined (5/ 5 in Kras/p53 and 11/11 in Kras), tumour nodules showed recrudescence of ERK phosphorylation ( Fig. 4d and Supplementary Fig. 7a ), suggesting that acquired resistance could be partly due to reactivation of MEK-ERK signalling despite ongoing treatment with selumetinib. We evaluated treatment-resistant nodules for ERK amplification (Supplementary Fig. 7b) , activation of parallel signalling pathways (Supplementary Fig. 7c) , and drug pharmacokinetics ( Supplementary  Fig. 7d ), and did not find consistent changes, suggesting more than one mechanism for pathway reactivation. Efforts to identify the diversity of mechanisms responsible for acquired resistance are ongoing.
This co-clinical study provides several insights and predictions that affect the interpretation of the concurrent human clinical trial. First, these results predict that combination therapy with docetaxel and selumetinib will be more effective than docetaxel alone in several subclasses of KRAS-mutant NSCLC. These data are consistent with the results of the human phase II clinical trial described in a recent press release (http://phx.corporate-ir.net/phoenix.zhtml?c5123810&p5 irol-newsArticle&ID51611800). However, our studies predict that concurrent mutation of LKB1 will confer primary resistance to combination therapy, possibly through activation of parallel signalling pathways such as AKT and SRC. As LKB1 status is not being prospectively assessed in the ongoing human clinical trial, inclusion of patients with cancers harbouring concurrent LKB1 mutations may blunt differences between treatment arms based solely on KRAS status. These results suggest that a retrospective analysis of p53 and LKB1 status in samples from the concurrent human clinical trial is warranted, and lead us to advocate prospective analysis in future clinical trials with sufficient enrolment to all strata to enable sufficiently powered sub-group analyses.
Beyond assessing genetic modulators, co-clinical studies allow for validation of biomarker strategies and discovery of mechanisms of resistance that may benefit future clinical trials. In this study, we observed the potential utility of FDG-PET imaging as a biomarker strategy for identifying an enriched responder population and predicting long-term outcome. Prior studies have suggested that lung tumour hypermetabolism at the time of diagnosis predicts poor outcome in response to conventional therapies 20, 24 , our current study further suggests that high baseline FDG avidity may predict poor response to targeted therapy with selumetinib combined with docetaxel. Specifically, loss of LKB1 function appears to confer increased FDG avidity, probably through upregulated expression of glucose transporters. As current approaches for assessing LKB1 status are not comprehensive, FDG-PET imaging may represent a practicable patient stratification strategy. Furthermore, the current preclinical study suggests a role for repeat FDG-PET imaging early in the course of treatment as a potential predictor of outcome, as metabolic changes may be apparent within 24 h of initiating therapy. In these studies, we also observed reactivation of the MEK-ERK a, Tumour volume was longitudinally assessed by MRI imaging in Kras and Kras/p53 mice treated with either docetaxel or docetaxel plus selumetinib. Data points represent median tumour volume relative to start of treatment for all available data at the indicated time point. b, Progression-free survival for Kras mice treated with either docetaxel or docetaxel plus selumetinib. Median survival for single and combination treatments was 6 weeks and 12 weeks respectively, with ***P 5 0.0003 by log-rank test. c, Progression-free survival for Kras/p53 mice treated with either docetaxel or docetaxel plus selumetinib. Median survival for single and combination treatments was 2 weeks and 4 weeks, respectively, with ***P , 0.0001 by log-rank test. Progression was defined as the time point when total tumour volume exceeded the baseline volume. d, Immunostaining of activation-specific phospho-ERK of tumours from Kras/p53 and Kras mice with acquired resistance to docetaxel and selumetinib treatment.
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signalling pathway in mice that became resistant to the combination of selumetinib and docetaxel. Although the exact mechanisms responsible for pathway reactivation remain to be elucidated, mechanisms of resistance discovered in co-clinical studies should be confirmed in human clinical trials by examining biopsy samples from patients who relapse on therapy. The ability to assess mechanisms of resistance in the preclinical setting may uncover rational combinatorial strategies that can be implemented in future clinical studies.
Building upon prior success using genetically engineered mouse models [25] [26] [27] , the current study demonstrates that co-clinical trials can provide data that has value beyond predicting the outcome of clinical trials, and can rapidly generate new clinically relevant hypotheses that can affect how the concurrent human clinical trial is analysed, and inform the design of future clinical studies. As similar efforts are undertaken in other cancer disease types, we anticipate that murine coclinical trials will enable more effective oncology drug development.
METHODS SUMMARY
Mice. Mouse strains harbouring a conditional activating mutation (G12D) at the endogenous Kras locus, conditional Lkb1 knockout, and conditional p53 knockout were described previously 7 . Genotypes were confirmed by PCR ( Supplementary  Fig. 8 ). All studies were performed on protocols approved by Dana-Farber Cancer Institute and University of North Carolina Animal Care and Use Committees, and all mice used are listed in Supplementary Table 4 . MRI quantification. 3D Slicer was used to reconstruct MRI volumetric measurements 28, 29 ( Supplementary Fig. 1a ). To assess variation between independent operators, Bland-Altman analysis was performed using quantification results from the two operators on a total of 16 MRI scan images (Supplementary Fig. 1b) . Pharmacokinetics. Docetaxel concentrations in serum, lung, and tumour nodules was determined using published doses (8 and 16 mg kg 21 ). Drug concentration was determined 3 h after the last dose (Supplementary Table 1 ). All serum concentrations were within the range found in the clinical setting 30 . Selumetinib was administered as previously described 19 , and pharmacokinetics in mice were also documented (Supplementary Table 3) . PET/CT studies. All murine FDG-PET/CT studies were performed with a preclinical small animal PET/CT system (Siemens Inveon) after injection with 14 MBq of 18 F-FDG. Mice used for PET/CT studies are listed in Supplementary  Table 5 . Human samples and clinical information. All human samples and clinical information were obtained under Institutional Review Board approved protocols (02-180 and 07-0120), and patient information is listed in Supplementary Tables 7  and 8 . A tissue microarray (TMA) was generated from genotyped human lung cancer samples as previously described 7 . The TMA was immunostained for phospho-ERK and scored by a pathologist blinded to patient information. Immunohistochemistry staining. Immunohistochemical analyses assessing phospho-ERK, activated caspase 3, and Ki-67 were performed as previously described 19 . Scoring was done by a pathologist, using the same parameters used for scoring human specimens.
